20 years of revenue, earnings, cash-flow and balance-sheet history from public filings.
Cullinan Oncology LLC (CGEM) operates in the BIOTECHNOLOGY industry and is headquartered in Cambridge, United States with about 109 employees. Its market capitalization is roughly $1 billion. In the fiscal year ended 2025-12-31, CGEM reported $0M in revenue and ($220M) in net income.
Cullinan Therapeutics, Inc., a clinical-stage biopharmaceutical company, develops therapies for autoimmune diseases and cancer in the United States.
Interactive charts & full statements →
| Income statement | TTM → 2026-06-30 | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 | 2020-12-31 | 2019-12-31 | 2018-12-31 | 2016-12-31 | 2015-12-31 | 2014-12-31 | 2013-12-31 | 2012-12-31 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Total Revenue | $0M | $0M | $0M | $0M | $0M | $19M | $19M | $0M | $0M | $0M | $0M | $0M | $0M | — |
| Gross Profit | — | $0M | $0M | $0M | $0M | $19M | $0M | $0M | $0M | $0M | $0M | $0M | $0M | — |
| Gross Margin % | — | — | — | — | — | 100.0% | -0.3% | — | — | — | — | — | — | — |
| Operating Income (EBIT) | ($222M) | ($242M) | ($197M) | ($191M) | $145M | ($68M) | ($60M) | ($22M) | ($15M) | $0M | $0M | $0M | ($1M) | — |
| Operating Margin % | — | — | — | — | — | -358.7% | -318.5% | — | — | — | — | — | — | — |
| Net Income | ($205M) | ($220M) | ($167M) | ($153M) | $111M | ($65M) | ($51M) | ($20M) | ($14M) | $0M | $0M | $0M | ($1M) | — |
| Net Margin % | — | — | — | — | — | -343.4% | -268.4% | — | — | — | — | — | — | — |
| EBITDA | ($208M) | ($220M) | ($167M) | ($190M) | ($132M) | ($68M) | ($60M) | ($22M) | ($15M) | — | — | — | — | — |
| Earnings Per Share (EPS) | $-3.43 | $-3.72 | $-3.11 | $-3.69 | $2.38 | $-1.47 | $-1.17 | $-19.68 | $-17.74 | — | — | — | — | — |
| Shares Outstanding (M) | 61M | 59M | 54M | 42M | 47M | 44M | 44M | 1M | 1M | — | — | — | — | — |
USD; $M / $B as marked. Newest period first. Source: public company filings (via Yahoo Finance aggregation).
| Quarterly income statement | 2026-06-30 | 2026-03-31 | 2025-12-31 | 2025-09-30 | 2025-06-30 | 2025-03-31 | 2024-12-31 | 2024-09-30 |
|---|---|---|---|---|---|---|---|---|
| Total Revenue | $0M | $0M | $0M | $0M | $0M | $0M | $0M | $0M |
| Gross Profit | — | $0M | $0M | — | $0M | $0M | $0M | $0M |
| Gross Margin % | — | — | — | — | — | — | — | — |
| Operating Income (EBIT) | ($57M) | ($54M) | ($55M) | ($56M) | ($76M) | ($55M) | ($55M) | ($49M) |
| Operating Margin % | — | — | — | — | — | — | — | — |
| Net Income | ($54M) | ($50M) | ($51M) | ($51M) | ($70M) | ($49M) | ($48M) | ($41M) |
| Net Margin % | — | — | — | — | — | — | — | — |
| EBITDA | ($54M) | ($54M) | ($51M) | ($51M) | ($70M) | ($48M) | ($47M) | ($40M) |
| Earnings Per Share (EPS) | $-0.87 | $-0.84 | $-0.86 | $-0.86 | $-1.19 | $-0.82 | $-0.81 | $-0.70 |
| Shares Outstanding (M) | 61M | 59M | 59M | 59M | 59M | 59M | 59M | 58M |
USD; $M / $B as marked. Newest period first. Source: public company filings (via Yahoo Finance aggregation).
| Cash flow | TTM → 2026-06-30 | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 | 2020-12-31 | 2019-12-31 | 2018-12-31 | 2016-12-31 | 2015-12-31 | 2014-12-31 | 2013-12-31 | 2012-12-31 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Cash from Operations (CFO) | ($159M) | ($176M) | ($145M) | ($134M) | ($127M) | ($43M) | ($30M) | ($21M) | ($14M) | $0M | $0M | $0M | ($1M) | — |
| Capital Expenditures (CapEx) | $37M | $0M | $0M | $0M | $1M | $1M | $0M | $0M | $0M | $0M | $0M | $0M | $0M | $0M |
| Free Cash Flow (FCF) | ($196M) | ($176M) | ($145M) | ($134M) | ($128M) | ($44M) | ($30M) | ($21M) | ($14M) | $0M | $0M | $0M | ($1M) | — |
| FCF Margin % | — | — | — | — | — | -232.4% | -157.2% | — | — | — | — | — | — | — |
USD; $M / $B as marked. Newest period first. Source: public company filings (via Yahoo Finance aggregation).
| Quarterly cash flow | 2026-06-30 | 2026-03-31 | 2025-12-31 | 2025-09-30 | 2025-06-30 | 2025-03-31 | 2024-12-31 | 2024-09-30 |
|---|---|---|---|---|---|---|---|---|
| Cash from Operations (CFO) | ($38M) | ($46M) | ($38M) | ($37M) | ($58M) | ($43M) | ($37M) | ($34M) |
| Capital Expenditures (CapEx) | $0M | $0M | $0M | $37M | $0M | $0M | $0M | $0M |
| Free Cash Flow (FCF) | ($38M) | ($46M) | ($38M) | ($74M) | ($58M) | ($43M) | ($37M) | ($34M) |
| FCF Margin % | — | — | — | — | — | — | — | — |
USD; $M / $B as marked. Newest period first. Source: public company filings (via Yahoo Finance aggregation).
| Balance sheet | 2026-06-30 | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 | 2020-12-31 | 2019-12-31 | 2018-12-31 | 2016-12-31 | 2015-12-31 | 2014-12-31 | 2013-12-31 | 2012-12-31 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Total Assets | $364M | $448M | $622M | $484M | $561M | $437M | $215M | $100M | $35M | $0M | $0M | $0M | $0M | $0M |
| Cash & Cash Equivalents | $79M | $88M | $83M | $98M | $156M | $60M | $168M | $63M | $34M | $0M | $0M | $0M | $0M | — |
| Total Liabilities | $42M | $40M | $31M | $30M | $26M | $12M | $14M | $140M | $55M | $1M | $1M | $1M | $1M | $0M |
| Total Debt (Short + Long-Term) | $1M | $1M | $1M | $1M | $2M | $0M | $0M | $0M | $0M | $1M | $2M | $2M | $2M | $0M |
| Total Shareholders' Equity | $322M | $409M | $590M | $454M | $535M | $425M | $199M | ($41M) | ($21M) | ($1M) | ($1M) | ($1M) | ($1M) | $0M |
USD; $M / $B as marked. Newest period first. Source: public company filings (via Yahoo Finance aggregation).
Quarterly statements, profitability ratios, price history, insider activity and institutional holders are in the interactive CGEM viewer.
About TickerBase · Data methodology & sources · Privacy · Terms